NEW YORK, July 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Biobanks - 2012 Year Book
GBI Research, the leading business intelligence provider, has released its latest report, "Biobanks - 2012 Year Book". It provides key data, information and analysis of 37 of the world's major biobanks. The report provides information on population-based biobanks, disease based biobanks, brain biobanks, stem cell biobanking, twin registries, children biobanks and many national biobanks. It also provides comprehensive analysis of funding, harmonization, the cost of biobanking, and partnership structure. In addition, the report reviews the factors determining the success and failure of biobanks.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research's team of industry experts.
Biobanking is a relatively new field with promising potential. It presents a host of opportunities and challenges. Funding patterns have changed as biobanks have evolved; in a comparative study of more than 100 biobanks around the world, the majority of biobanks were found to be stand-alone, and were entirely funded by the government of the country. Around 70% of biobanks are stand-alone, whereas only 30% are partnered with other biobanks or institutions. With globalization and a growing interest in trans-national sharing of biobank resources, there is an increasing push to harmonize biobank processes and regulations. The process of setting up a new biobank is the most costly phase of a biobank's development and lifespan. The maintenance cost of a biobank is marginal compared to the cost of set-up.
- A comprehensive study of 37 major biobanks in the world along with the current trends in biobanking.- A detailed account of population-based biobanks, disease-based biobanks, brain biobanks, stem cell biobanking, twin registries, children biobanks and many national biobanks.- A comparative study of the major issues concerning biobanks including funding, harmonization, the cost of biobanking, partnership structure, and regulatory and ethical issues. - In-depth analysis of the major developments in the leading segments of biobanks with key emphasis on major challenges in the biobanking sector.
Reasons to buy
- Evaluate major biobanks in the world, their service providers, research collaborations and private sector involvement. - Analyze issues of funding, harmonization, the cost of biobanking, and partnership structure that determine strength and limitation of a biobank. - Develop strategic initiatives by understanding the key focus of research of the leading biobanks.- Accelerate and strengthen your market position by identifying key biobanks for mergers, acquisitions and strategic partnerships to accelerate research and development.- Devise better strategies through the understanding of key drivers and barriers in the market.- Develop understanding on recent developments in biobanking regulatory frameworks and ethical issues like informed consent, withdrawal of ownership, confidentiality and commercialization.Table of Contents
1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 72 Introduction 83 Biobanks – The Basics 93.1 Introduction 93.2 Types of Biobanks 93.2.1 DNA Banks 93.2.2 Cell Culture Banks 93.2.3 Pathologically Altered Vital Tissue Banks 103.3 Benefits of Biobanks 103.4 Biobanks - Brief History 113.4.1 Framingham Heart Study 113.4.2 Monitoring of Cardiovascular Diseases Project 123.5 Characteristics of a Biobank 123.6 Classification of Biobanks 123.6.1 Population-Based Biobanks 123.6.2 Disease-Based Biobanks 124 Biobanks – Overview 134.1 Introduction 134.2 National Biobanks 134.3 Funding Structure in Biobanking 134.3.1 Funding Issues 144.3.2 Private Funding 144.3.3 Public-Private Funding 144.3.4 Public Funding 154.4 Partnerships Structure in Biobanking 164.4.1 Comparison of Partnerships 174.5 Increasing Harmonization 184.5.1 Biobanks Participating in Harmonization 184.6 Expert Centers – Trans-national Research 194.7 Cost of Biobanks 204.7.1 Sample Collection 204.7.2 Biobank Set Up 204.7.3 Maintenance of the Biobank 204.7.4 Research Costs 204.7.5 Outreach Activities 204.7.6 Conclusion 214.8 SWOT Analysis of Biobanking Sector 214.8.1 Strengths 214.8.2 Weaknesses 224.8.3 Opportunities 224.8.4 Threats 225 Biobanks – Population-based Biobanks 235.1 Introduction 235.1.1 Cohort study or Panel Study 245.2 deCODE Genetics 245.2.1 Background Information 245.2.2 Organizational Structure 255.2.3 Financial Support 255.2.4 Collaborations 265.2.5 Future Plan 265.3 CARTaGENE 265.3.1 Background Information 265.3.2 Organizational Structure 275.3.3 Financial Support 275.3.4 Collaborations 275.3.5 Future Plan 285.4 UK DNA Banking Network 285.4.1 Background Information 285.4.2 Organizational Structure 285.4.3 Financial Support 295.4.4 Collaborations 305.4.5 Future Plan 315.5 European Network for Genetic and Genomic Epidemiology (ENGAGE) 315.5.1 Background Information 315.5.2 Organizational Structure 325.5.3 Financial Support 335.5.4 Collaborations 335.5.5 Future Plan 335.6 TRANSBIG Network 345.6.1 Background Information 345.6.2 Organizational Structure 355.6.3 Financial Support 355.6.4 Collaborations 365.6.5 Future Plan 365.7 Iceland Health Sector Database 365.7.1 Background Information 365.7.2 Organizational Structure 365.7.3 Financial Support 365.7.4 Collaborations 365.7.5 Future Plan 375.8 Tumor Bank of Castilla-Leon (BTCyL) 375.8.1 Background Information 375.8.2 Organizational Structure 375.8.3 Financial Support 385.9 Telethon Genetic Biobank Network 385.9.1 Background Information 385.9.2 Organizational Structure 385.9.3 Financial Support 395.9.4 Collaborations 395.9.5 Future Plan 405.10 EuroBiobank 405.10.1 Background Information 405.10.2 Organizational Structure 415.10.3 Financial Support 425.10.4 Collaborations 425.10.5 Future Plan 435.11 Latvian Biobank 435.11.1 Background Information 435.11.2 Organizational Structure 435.11.3 Financial Support 435.11.4 Collaborations 435.11.5 Future Plan 435.12 Canadian Partnership for Tomorrow Project 435.12.1 Background Information 435.12.2 Organizational Structure 435.12.3 Financial Support 435.12.4 Collaborations 445.12.5 Future Plan 446 Biobanks – Disease-Based Biobanks 456.1 Introduction 456.2 Cancer Biobanks 466.2.1 Victorian Cancer Biobank 466.2.2 The Ontario Tumor Bank 466.2.3 The Canadian Tumor Repository Network 476.2.4 Tumor Tissue Repository 476.3 Brain Biobanking 486.3.1 Huddinge Brain Biobank 486.3.2 MRC London Brain Bank for Neurodegenerative Diseases 496.3.3 The MRC HIV Brain and Tissue Bank 496.3.4 The MRC Sudden Death Brain and Tissue Bank 506.3.5 CJD Brain and Tissue Bank 506.3.6 UK Multiple Sclerosis Tissue Bank 506.3.7 South West Dementia Brain Bank 516.3.8 Queen Square Brain Bank for Neurological Disorders 516.3.9 Newcastle Brain Tissue Resource 526.4 Twin Registries 526.4.1 GenomEUTwin 526.4.2 The Australian Twin Registry 536.4.3 The Mid-Atlantic Twin Registry 546.5 Stem Cell Biobanking 556.5.1 The Singapore Stem Cell Consortium 556.5.2 Coriell Stem Cell Biobank 556.5.3 Swiss Stem Cells Bank 566.6 Children Biobanks 566.6.1 The Norwegian Mother and Child Cohort Study (MoBa) 576.6.2 Avon Longitudinal Study of Parents and Children (ALSPAC) 576.7 Largest Biobanks and Biobanking Networks in the World 586.7.1 The Public Population Project in Genomics (P3G) 586.7.2 Estonian Genome Project (EGP) 586.7.3 Singapore Tissue Network 596.7.4 UK Biobank 596.7.5 International Genomics Consortium (IGC) 607 Biobanks – Regulatory and Ethical Issues and Challenges 627.1 Introduction 627.2 Issues Related to Biobanking 627.2.1 Informed Consent 627.2.2 Confidentiality 627.2.3 Returning Results from Biobank 627.2.4 Secondary Use of Samples Collected Over Time 637.3 Challenges Faced by Biobanks 647.4 Conclusions 648 Biobanks – Appendix 658.1 Market Definitions 658.2 Abbreviations 658.3 Sources 678.4 Research Methodology 688.4.1 Coverage 688.4.2 Secondary Research 688.4.3 Primary Research 688.4.4 Expert Panel Validation 698.5 Contact Us 698.6 Disclaimer 69
List of Tables
1.1 List of TablesTable 1: Comparison of Funding Sources for Eight Major Biobanks - 2010 15Table 2: Biobanks, International Biobanks involved in Harmonization Programs 18Table 3: Biobanks, Applications and Strengths of Population-based Biobanks 23Table 4: Biobanks, deCODE Genetics Overview 24Table 5: Biobanks, CARTaGENE Overview 27Table 6: Biobanks, Type and Number of Sample Collections Available at UKDBN- 2010 29Table 7: Biobanks, UK DNA Banking Network Overview 30Table 8: Biobanks, European Network for Genetic and Genomic Epidemiology Overview 32Table 9: Biobanks, TRANSBIG Network Overview 34Table 10: Biobanks, Iceland Health Sector Database Overview 37Table 11: Biobanks, Biobanks with Sample Sizes of ?200,000, 2010 45Table 12: Biobanks, Largest Children Biobank Projects around the World - 2010 56
List of Figures
1.2 List of FiguresFigure 1: Biobanks, Global, Anticipated Benefits 10Figure 2: Biobanks, Global, Type of Data and Sources Obtained from Biobanks 11Figure 3: Biobanks, Classification: Type of Sample Availability 13Figure 4: Biobanks, Type of Partnerships, Europe (%), 2010 16Figure 5: Biobanks, Ownership of Biobanks, Europe, 2010 17Figure 6: Biobanks, Global, Expert Centers Facilitating Trans-national Research 19Figure 7: SWOT Analysis of Biobanking Sector 21Figure 8: Biobanks, ENGAGE, Funding Sources (%) - 2011 33Figure 9: Biobanks, TRANSBIG, Network Funding Sources (%) - 2011 35Figure 10: Biobanks, EuroBiobank, Main Objectives - 2011 41Figure 11: Biobanks, Frequency of Registrants by Age at Mid-Atlantic Twin Registry - 2011 54Figure 12: Biobanks, Major Issues Threatening Biobanks - 2011 63
Companies MentionedTo order this report:Genomics Industry: Biobanks - 2012 Year Book
MoreMarket Research Report
Check ourIndustry Analysis and Insights
Intl: +1 805-652-2626